Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CART19”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)UnknownNCT03896854
What this trial is testing

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 15
Large-scale testing (Phase 3)UnknownNCT03391739
What this trial is testing

CART-19 Cells For R/R B-ALL

Who this might be right for
Relapsed/Refractory B-cell ALL
Fujian Medical University 20
Testing effectiveness (Phase 2)UnknownNCT02081937
What this trial is testing

CART-19 Immunotherapy in Mantle Cell Lymphoma

Who this might be right for
Hematopoietic/Lymphoid CancerNon-hodgkin Lymphoma,B CellMantle Cell Lymphoma
Chinese PLA General Hospital 2
Not applicableAvailableNCT03601442
What this trial is testing

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals
Not applicableUnknownNCT06160362
What this trial is testing

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Henan Cancer Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06839976
What this trial is testing

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Who this might be right for
SLESystemic Lupus Erythematosus (SLE)CAR T Cell+4 more
Children's Hospital of Philadelphia 24
Testing effectiveness (Phase 2)Ended earlyNCT02935543
What this trial is testing

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Who this might be right for
Leukemia, Acute Lymphoblastic
University of Pennsylvania 1
Large-scale testing (Phase 3)UnknownNCT03391726
What this trial is testing

CART-19 Cells for R/R B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Fujian Medical University 20
Testing effectiveness (Phase 2)Ended earlyNCT02794246
What this trial is testing

CART-19 Post-ASCT for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 6
Not applicableStudy completedNCT02476734
What this trial is testing

FDG-PET/CT Imaging as Early Predictor of DP

Who this might be right for
Lymphoma
Abramson Cancer Center at Penn Medicine 9
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Testing effectiveness (Phase 2)UnknownNCT03455972
What this trial is testing

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 15
Early research (Phase 1)Study completedNCT01029366
What this trial is testing

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
University of Pennsylvania 26
Early research (Phase 1)UnknownNCT02810223
What this trial is testing

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Beijing Sanwater Biological Technology Co., Ltd. 20
Early research (Phase 1)UnknownNCT02799550
What this trial is testing

Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL

Who this might be right for
Leukemia
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 10
Early research (Phase 1)UnknownNCT02924753
What this trial is testing

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Henan Cancer Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01626495
What this trial is testing

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
University of Pennsylvania 73
Early research (Phase 1)WithdrawnNCT05037669
What this trial is testing

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
University of Pennsylvania
Testing effectiveness (Phase 2)UnknownNCT03544021
What this trial is testing

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

Who this might be right for
Leukemia, Lymphocytic, Acute
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 10
Testing effectiveness (Phase 2)Looking for participantsNCT04276870
What this trial is testing

Orphan Indications for CD19 Redirected Autologous T Cells

Who this might be right for
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALLInfants With Very High Risk KMT2A B-ALLPatients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
Stephan Grupp MD PhD 133
Load More Results